Resistance to the Insulin and Elevated Level of Androgen: A Major Cause of Polycystic Ovary Syndrome

被引：99

作者：

Ding, Haigang ^{[1
,2
]}

Zhang, Juan ^{[1
,2
]}

Zhang, Feng ^{[1
,2
]}

Zhang, Songou ^{[3
]}

Chen, Xiaozhen ^{[3
]}

Liang, Wenqing ^{[4
]}

Xie, Qiong ^{[5
]}

机构：

[1] Shaoxing Matern & Child Hlth Care Hosp, Dept Gynecol, Shaoxing, Peoples R China

[2] Shaoxing Univ, Obstet & Gynecol Hosp, Shaoxing, Peoples R China

[3] Shaoxing Univ, Coll Med, Shaoxing, Peoples R China

[4] Zhejiang Chinese Med Univ, Med Res Ctr, Zhoushan Hosp Tradit Chinese Med, Zhoushan, Peoples R China

[5] Zhejiang Chinese Med Univ, Dept Gynecol, Zhoushan Hosp Tradit Chinese Med, Zhoushan, Peoples R China

来源：

FRONTIERS IN ENDOCRINOLOGY | 2021年 / 12卷

关键词：

polycystic ovary syndrome (PCOS); insulin resistance; androgen; hyper-androgenemia; endocrine disorder; IMPAIRED GLUCOSE-TOLERANCE; ANTI-MULLERIAN HORMONE; METABOLIC SYNDROME; DIABETES-MELLITUS; BIOCHEMICAL HYPERANDROGENISM; ENDOCRINE PARAMETERS; PREMENOPAUSAL WOMEN; MOLECULAR DEFECTS; CONCEPTION RATES; FOLLICULAR-FLUID;

D O I：

10.3389/fendo.2021.741764

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PCOS has a wide range of negative impacts on women's health and is one of the most frequent reproductive systemic endocrine disorders. PCOS has complex characteristics and symptom heterogeneity due to the several pathways that are involved in the infection and the absence of a comm14on cause. A recent study has shown that the main etiology and endocrine aspects of PCOS are the increased level of androgen, which is also known as "hyperandrogenemia (HA)" and secondly the "insulin resistance (IR)". The major underlying cause of the polycystic ovary is these two IR and HA, by initiating the disease and its severity or duration. As a consequence, study on Pathogenesis is crucial to understand the effect of "HA" and "IR" on the pathophysiology of numerous symptoms linked to PCOS. A deep understanding of the pattern of the growth in PCOS for HA and IR can help ameliorate the condition, along with adjustments in nutrition and life, as well as the discovery of new medicinal products. However, further research is required to clarify the mutual role of IR and HA on PCOS development.

引用

页数：14

共 158 条

[1] Hyperandrogenic origins of polycystic ovary syndrome - implications for pathophysiology and therapy [J].

Abbott, David H. ;

Dumesic, Daniel A. ;

Levine, Jon E. .

EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2019, 14 (02) :131-143

[2] Nonhuman primate models of polycystic ovary syndrome [J].

Abbott, David H. ;

Nicol, Lindsey E. ;

Levine, Jon E. ;

Xu, Ning ;

Goodarzi, Mark O. ;

Dumesic, Daniel A. .

MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2013, 373 (1-2) :21-28

[3]

Achard C., 1921, Bull Acad Natl Med, V86, P51

[4] Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance [J].

Amato, M. C. ;

Vesco, R. ;

Vigneri, E. ;

Ciresi, A. ;

Giordano, C. .

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2015, 38 (12) :1319-1326

[5] Proteomics of Follicular Fluid From Women With Polycystic Ovary Syndrome Suggests Molecular Defects in Follicular Development [J].

Ambekar, Aditi S. ;

Kelkar, Dhanashree S. ;

Pinto, Sneha M. ;

Sharma, Rakesh ;

Hinduja, Indira ;

Zaveri, Kusum ;

Pandey, Akhilesh ;

Prasad, T. S. Keshava ;

Gowda, Harsha ;

Mukherjee, Srabani .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (02) :744-753

[6] A prospective dose-finding study of the amount of thermal energy required for laparoscopic ovarian diathermy [J].

Amer, SAK ;

Li, TC ;

Cooke, ID .

HUMAN REPRODUCTION, 2003, 18 (08) :1693-1698

[7] Metabolic and Hormonal Changes Induced by Pioglitazone in Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Clinical Trial [J].

Aroda, Vanita R. ;

Ciaraldi, Theodore P. ;

Burke, Paivi ;

Mudaliar, Sunder ;

Clopton, Paul ;

Phillips, Susan ;

Chang, R. Jeffrey ;

Henry, Robert R. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (02) :469-476

[8] Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: A multicenter, double blind, placebo-controlled trial [J].

Azziz, R ;

Ehrmann, D ;

Legro, RS ;

Whitcomb, RW ;

Hanley, R ;

Fereshetian, AG ;

O'Keefe, M ;

Ghazzi, MN .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (04) :1626-1632

[9] Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline [J].

Azziz, Ricardo ;

Carmina, Enrico ;

Dewailly, Didier ;

Diamanti-Kandarakis, Evanthia ;

Escobar-Morreale, Hector F. ;

Futterweit, Walter ;

Janssen, Onno E. ;

Legro, Richard S. ;

Norman, Robert J. ;

Taylor, Ann E. ;

Witchel, Selma F. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (11) :4237-4245

[10] The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report [J].